MRK Stock Recent News

Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.

In the closing of the recent trading day, Merck (MRK) stood at $130.20, denoting a -1.24% change from the preceding trading day.

Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and President, Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway. Good morning, everybody, and welcome to the Second Day of the conference.

Merck is focused on second and third-generation opportunities in the cardiometabolic drugs market, which includes treatments for obesity, the drugmaker said at a healthcare conference on Tuesday.

Merck's Keytruda drug has shown promising results in treating bowel cancer, according to Germany's largest newspaper. Merck has significantly increased its oncology portfolio, with Keytruda achieving nine U.S. approvals in earlier-stage cancers. The company's phase III trials targeting earlier-stage cancers have shown impressive outcomes, including a reduction in the risk of death for patients with lung and renal cell cancers.

Several notable billionaire hedge fund managers have bought shares of Pfizer or Merck recently. Despite immediate or upcoming headwinds, both companies look like strong picks for income investors.

DARMSTADT, Germany--(BUSINESS WIRE)--Merck opened its expanded Life Science distribution center in Schnelldorf, Germany. The € 180 investment added 25,000 square meters to the site.

The latest trading day saw Merck (MRK) settling at $129.45, representing a +0.57% change from its previous close.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

Merck & Co., Inc. (NYSE:MRK ) Investor Event at ASCO 2024 June 3, 2024 7:00 PM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Dean Li - President of Merck Research Labs Eliav Barr - Chief Medical Officer & Head of Global Clinical Development Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Joanne Monahan - Senior Vice President, US Oncology Conference Call Participants Carter Gould - Barclays Chris Schott - JPMorgan Evan Seigerman - BMO Capital Markets Akash Tewari - Jefferies Steve Scala - TD Cowen Chris Shibutani - Goldman Sachs Trung Huynh - UBS Mohit Bansal - Wells Fargo Dan Ziment - Morgan Stanley Daina Graybosch - Leerink Partners Operator Thank you for standing by. Welcome to the Merck & Co., Inc. Investor Event at the American Society of Clinical Oncology Annual Meeting.